How It Works
When ordering a CCTA for patients, clinicians can include Heartflow Plaque Analysis to enhance their diagnostic confidence and potentially improve patient outcomes through tailored treatment strategies.
Heartflow's Plaque Analysis represents a significant advancement in proactive care for CAD. As a non-invasive, AI-enabled disease management tool, it provides clinicians a better path towards accurate risk assessment and personalized care.
Demonstrated accuracy in quantifying and characterizing coronary plaque so clinicians
can be confident in their diagnosis
and management.
Quantifies calcified, non-calcified, and low attenuation plaque to help clinicians assess extent of CAD risk and provide personalized treatment.
Achieve better treatment decisions earlier to
reduce risk and adverse events associated with
cardiovascular disease.
for patients in a high total plaque volume cohort, compared to a low plaque volume cohort.2
of patients with a Calcium Score of 0 were reclassified to a more aggressive therapy approach.3
of patients in the DECODE Study received a refined management plan when Plaque Analysis was utilized.3
When ordering a CCTA for patients, clinicians can include Heartflow Plaque Analysis to enhance their diagnostic confidence and potentially improve patient outcomes through tailored treatment strategies.
[Plaque Analysis] can actually help guide our treatment by identifying high risk plaque components…It’s treating the whole patient and their overall risk, not just the one component of that risk.
”